Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022
22 Febrero 2022 - 3:05PM
Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development
and manufacturing organization (CDMO) dedicated to solving complex
formulation and manufacturing challenges primarily in small
molecule therapeutic development, today announced that the company
will release financial results for the fourth quarter and year-end
2021 after the market close on Tuesday, March 1, 2022. Recro’s
management team will host a conference call and audio webcast at
4:30 p.m. ET on Tuesday, March 1, 2022 to discuss the financial
results and recent operational highlights.
To access the live conference call please dial
(844) 243-4691 from the U.S. or (225) 283-0379 from outside the
U.S. at least ten minutes prior to the start time and reference
conference ID 7549058. Those interested in listening to the
conference call live via webcast may do so by visiting the “Events”
page in the Investor section of the Company’s
website, www.recrocdmo.com. In addition, an archived webcast
will be available on the Company’s website approximately two hours
after the event and will be available for 30 days.
About RecroRecro (NASDAQ: REPH)
is a bi-coastal contract development and manufacturing organization
(CDMO) with capabilities spanning pre-Investigational New Drug
(IND) development to commercial manufacturing and packaging for a
wide range of therapeutic dosage forms with a primary focus in the
area of small molecules. With an expertise in solving complex
manufacturing problems, Recro is a leading CDMO providing
therapeutic development, end-to-end regulatory support, clinical
and commercial manufacturing, aseptic fill/finish, lyophilization,
packaging and logistics services to the global pharmaceutical
market.
In addition to our experience in handling DEA
controlled substances and developing and manufacturing
modified-release dosage forms, Recro has the expertise to deliver
on our clients’ pharmaceutical development and manufacturing
projects, regardless of complexity level. We do all of this in our
best-in-class facilities, which total 145,000 square feet, in
Gainesville, Georgia and San Diego, California.
For more information about Recro’s CDMO
solutions, visit recrocdmo.com.
Contacts:
Stephanie Diaz (Investors)(CFO)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Ryan D. Lake
Recro
770-531-8365
ryan.lake@recroCDMO.com
Recro Pharma (NASDAQ:REPH)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Recro Pharma (NASDAQ:REPH)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Recro Pharma Inc (NASDAQ): 0 recent articles
Más de Artículos de Noticias